Shah's claim is that early-stage mortality is a process failure, not a law of nature. The ecosystem prices angel investing at one success in ten; Inflection Point Ventures says its own rate is closer to five in ten, and puts the gap down to what happens on either side of the wire — close to 700 ideas a month through five layers of filtering to four or five cheques, then a base of 14,000-plus investors across 55-plus countries put to work on hiring, customers and the next round. His framing is blunt: capital is about 25% of a founder's problem and execution is the other 75%. It is also why coming in one round early is the whole return — enter at a ₹5 crore valuation rather than ₹20 crore and you are at 20x where the later investor is at 5x when the company reaches ₹100 crore. He is a CFO by trade — twelve years in textiles, an IPO led at 28, three years inside Ola — who started writing angel cheques in 2014 to sit closer to the problem rather than to compound wealth. The rest is operating doctrine: funding winter was a phrase investors coined to buy cheaper, D2C is a channel and not a story, deep tech dies at monetisation rather than in the lab, an acquisition is a home rather than a failure, and a startup portfolio below 25 names is just hoping. Around it sits new machinery — a pre-seed programme writing $100K for 8%, and a Series A/B fund first-closed at $12 million — built so IPV never has to hand a winner to somebody else.
Worth your time if you are
Salaried professionals wondering if ₹1 lakh buys a seat at the angel table
Pre-product founders who cannot yet show a P&L
Founders weighing an acquisition offer against another round
Deep-tech teams that have built the science but not the price
New family offices deciding what share of wealth goes to startups